

ASCO 2023

## **Highlights from the ASCO congress 2023 for Ribociclib**

### **Ribociclib**

Resources related to Ribociclib

A green rectangular graphic with black triangular corners. The text "Abstract #1063" is centered in a white, monospaced font.

Abstract  
#1063

---

#### **A subgroup analysis of the RIGHT Choice trial**

#### **A subgroup analysis of the RIGHT Choice trial**

Outcomes with 1L ribociclib + ET vs. physician's choice combination chemotherapy by age in pre/perimenopausal patients with aggressive HR+/HER2– aBC

[See more details](#)

Hide details

A horizontal green banner with black triangular corners at the top-left and bottom-right. The text "Abstract #1125" is centered in white.

# Abstract #1125

---

**A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58**

**A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58**

Ribociclib vs. palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) aBC

[See more details](#)

Hide details

**Abbreviations:**

1L: first line; ET: endocrine therapy; aBC: advanced breast cancer; HR+: hormone receptor positive, HER2– : human epidermal growth factor receptor 2 negative; AI: aromatase inhibitor; FUL: fulvestrant; ET: endocrine monotherapy, CT: chemotherapy

---

**Source URL:** <https://www.pro.novartis.com/ch-de/asco-2023>